Cite
HARVARD Citation
O'Brien, S. et al. (n.d.). Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American journal of hematology. 93 (11), pp. 1318-1326. [Online].